|
|
Management of a colon cancer patient complicated with COVID-19 |
YE Ziqi( ),HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng*( ),LU Xiaoyang*( ) |
Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China |
|
|
Abstract Objective: To explore the feasibility of radical resection for cancer patients complicated with coronavirus disease 2019 (COVID-19). Methods: The management and clinical outcome of a sigmoid cancer patient with COVID-19 were analyzed. Results: The inflammation indicators and fever of this patient were effectively controlled and the lung lesions remained stable after active anti-viral treatment, then the radical colorectomy was performed after the viral negative conversion for twice. Conclusion: The case indicates that radical resection can be performed in SARS-CoV-2 patients with twice-negative SARS-CoV-2 nucleic acid testing results.
|
Received: 04 March 2020
Published: 27 March 2020
|
|
Corresponding Authors:
RAO Yuefeng,LU Xiaoyang
E-mail: ziqiye@zju.edu.cn;raoyf@zju.edu.cn;luxiaoyang@zju.edu.cn
|
一例肿瘤合并2019冠状病毒病(COVID-19)患者的治疗决策分析
目的: 探讨亟待进行肿瘤根治术的患者合并2019冠状病毒病(COVID-19)后如何选择手术治疗时机。方法: 详细分析1例乙状结肠癌合并COVID-19患者的治疗过程,以及该患者在病毒两次转阴后进行根治性手术后的恢复情况。结果: 患者术后恢复良好,炎症指标、发热等临床表现改善,肺部病灶也维持稳定。结论: 对于亟待进行肿瘤根治术且合并COVID-19的患者,在符合病毒核酸检测两次阴性之后进行肿瘤根治术是可行的。
关键词:
2019冠状病毒病,
严重急性呼吸综合征冠状病毒2,
新型冠状病毒肺炎,
结肠癌,
根治性手术,
治疗时机
|
|
[1] |
KAMBOJ M , SEPKOWITZ K A . Nosocomial infections in patients with cancer[J]. Lancet Oncol, 2009, 10 (6): 589- 597
doi: 10.1016/S1470-2045(09)70069-5
|
|
|
[2] |
LI J Y , DUAN X F , WANG L P et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014, 2014 286170
doi: 10.1155/2014/286170
|
|
|
[3] |
LONGBOTTOM E R , TORRANCE H D , OWEN H C et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways[J]. Ann Surg, 2016, 264 (2): 370- 377
doi: 10.1097/SLA.0000000000001484
|
|
|
[4] |
SICA A , MASSAROTTI M . Myeloid suppressor cells in cancer and autoimmunity[J]. J Autoimmun, 2017, 85 117- 125
doi: 10.1016/j.jaut.2017.07.010
|
|
|
[5] |
LIANG W , GUAN W , CHEN R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21 (3): 335- 337
doi: 10.1016/S1470-2045(20)30096-6
|
|
|
[6] |
中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[A/OL].国卫办医函〔2020〕184号.(2020-03-03)[2020-03-10].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7)[A/OL]. No.184〔2020〕 of the General Office of the National Health Commission. (2020-03-03)[2020-03-10]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. (in Chinese)
|
|
|
[7] |
HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
|
|
|
[8] |
WANG D, HU B, HU C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J/OL]. JAMA, 2020: e201585. DOI: 10.1001/jama.2020.1585.
|
|
|
[9] |
HEINEMANN V , VON WEIKERSTHAL L F , DECKER T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15 (10): 1065- 1075
doi: 10.1016/S1470-2045(14)70330-4
|
|
|
[10] |
黄耿文 . 新型冠状病毒肺炎疫情下实施普通外科手术的思考和建议[J]. 中华普通外科杂志, 2020, 29 (2): 127- 130 HUANG Gengwen . Thoughts and advices on performing procedures in general surgery during the outbreak of novel coronavirus pneumonia[J]. Chinese Journal of General Surgery, 2020, 29 (2): 127- 130
doi: 10.7659/j.issn.1005-6947.2020.02.001
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|